An Act to amend 94.55 (1); to create 94.55 (5) of the statutes; Relating to: regulating hemp-derived cannabinoid products.
Impact
If enacted, AB747 would significantly impact state laws focusing on hemp and cannabinoid product safety. It mandates that manufacturers submit each batch of their products for independent testing by accredited laboratories to ensure product safety and compliance with stated cannabinoid levels. This legislation would enhance consumer confidence in hemp-derived products while promoting accountability within the industry. Additionally, it would stipulate that products must bear comprehensive labels detailing ingredients, serving sizes, cannabinoid profiles, allergens, and important health warnings, thus increasing transparency for consumers.
Summary
Assembly Bill 747 aims to establish a regulatory framework for the sale and distribution of hemp-derived cannabinoid products in Wisconsin. The bill modifies the definition of hemp to include various cannabinoids extracted from the plant, specifically addressing products that contain delta-6-THC, delta-8-THC, delta-9-THC, and delta-10-THC. A key aspect of the bill is the emphasis on ensuring these products are safe for consumers, particularly minors, by setting an age restriction of 21 for purchases and introducing various labeling and testing requirements for manufacturers.
Contention
The bill has been a topic of debate among stakeholders. Proponents argue that the introduction of strict regulations for hemp-derived cannabinoid products would help prevent the sale of unsafe products to consumers, particularly minors. However, opponents may view the additional regulatory hurdles as burdensome for manufacturers, potentially limiting product variety and access. concerns about the safety and marketing practices in a rapidly growing industry have underscored discussions around the bill, reflecting broader questions about the regulation of cannabinoid products.